Pure Global AI
NCT06308510Not yet recruiting

Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer

Erasmus Medical CenterClinicalTrials.govother
Verified
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
collection additional peritoneal lavage fluid
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Erasmus Medical Center
Location
Rotterdam, Netherlands
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2024
End date
Jul 01, 2028
Enrollment
63 participants
Primary outcome

Sensitivity mFast-SeqS

Summary

Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis
 compared to conventional cytology and imaging techniques. Our aim is to establish whether
 aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold
 value as an additional staging and tumor evaluation method in GC patients.

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06308510
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06308510 through Pure Global AI's free database. This phase not specified trial is sponsored by Erasmus Medical Center and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 63 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.